Form 4 for DNLI Denali Therapeutics Inc.

Accepted 2021-07-23 00:00:00 ET · period of report 2021-07-21 · accession 0001714899-21-000060 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2021-07-23	2021-07-21	DNLI	SATO VICKI L	Dir	S - Sale	$65.13	-1,666	132.8K	-1%	-$108.5K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-07-21	S	D	400	$64.25	134,097	D	—	—	(F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $63.60 to $64.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 2,074 restricted stock units.
2	Common	Common Stock	2021-07-21	S	D	866	$65.24	133,231	D	—	—	(F4) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $64.61 to $65.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 2,074 restricted stock units.
3	Common	Common Stock	2021-07-21	S	D	400	$65.78	132,831	D	—	—	(F5) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $65.63 to $66.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 2,074 restricted stock units.